Moderna (MRNA), an undervalued name in the biotech space, rose to prominence during the COVID-19 pandemic. This occurred when its mRNA-based COVID-19 vaccine was one of the first to be granted emergency-use authorization and distributed globally. This opportunity also validated Moderna’s mRNA platform’s effectiveness and scalability, boosting the company’s stock price by more than 1,200% between 2020 and 2022.
Another such clinical-stage contender generating growing excitement is Intellia Therapeutics (NTLA), a CRISPR/Cas9-based gene-editing company. Intellia aims to provide one-time, curative treatments for serious genetic diseases. Intellia’s stock has fallen 1.9% year-to-date, while the broader market, as tracked by the S&P 500 Index ($SPX), has risen 6%.
